The calculation depends on two linked judgments: whether a cell is a viable tumor cell and whether its membrane shows partial or complete PD-L1 staining. Membrane staining, rather than staining in surrounding tissue, is the relevant signal for the score. Keeping these judgments separate helps prevent immune or other non-tumor cells from entering the numerator.
Partial membrane staining is counted alongside complete membrane staining, so the assessment does not require an entirely stained cell boundary. The important condition is that the qualifying pattern is present on a viable tumor cell. This rule allows the score to capture differing degrees of membranous PD-L1 expression while retaining a consistent tumor-cell denominator.
Interpretation can be influenced by how confidently the evaluator identifies viable tumor cells and separates them from immune or other surrounding cells. Because the result is a proportion, inconsistent classification can change the reported percentage even when the stained specimen is the same. Standardized scoring therefore matters when comparing specimens or research studies.
TPS assigns relevance to staining on tumor-cell membranes, whereas surrounding immune cells are distinguished from that population rather than treated as tumor cells. This distinction matters because a tissue section can contain both tumor and immune cells. Mixing those populations would change the biological interpretation of the reported proportion and reduce consistency across assessments.
During assessment, a pathologist examines the immunohistochemically stained tissue, identifies the viable tumor-cell population, checks relevant cells for partial or complete membrane staining, and calculates the proportion meeting that criterion. Attention to cell identity precedes the percentage calculation. This workflow links the visual staining pattern in the specimen to a standardized numeric result.
The measure helps characterize the tumor immune environment and supports biomarker assessment in selected cancers. In appropriate settings, the result can contribute to treatment decisions involving PD-1 or PD-L1 inhibitor therapy. It also provides a common way to report tumor-cell PD-L1 staining, which supports comparison across tissue specimens and cancer research studies.